Home/ Stocks/ KTTA

Pasithea Therapeutics Corp. Common Stock

KTTA XNAS

$0.77 -0.01 (-0.70%) ▼ 15-min delayed

Open

$0.77

High

$0.79

Low

$0.75

Volume

725.6K

Market Cap

$17.78M

About Pasithea Therapeutics Corp. Common Stock

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Sector: PHARMACEUTICAL PREPARATIONS Employees: 4 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	N/A	$-3,037,420	$-0.41
Q2 2025	N/A	$-3,716,157	$-0.66
Q1 2025	N/A	$-3,563,238	$-1.61
FY 2024	N/A	$-13,904,584	N/A

Earnings & Analyst Ratings

Next Earnings: Wed, May 13, 2026

Calendar →

Related Market News

No specific coverage for KTTA yet. Check out our latest market news or earnings calendar.

Get KTTA Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Pasithea Therapeutics Corp. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.